发明公开
- 专利标题： CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS
- 专利标题（中）： 作者CXCR4拮抗剂是治疗癌症和自身免疫性疾病的治疗
-
申请号： EP01931279.2申请日： 2001-05-09
-
公开(公告)号： EP1286684A2公开(公告)日： 2003-03-05
- 发明人: TUDAN, Christopher, R. , MERZOUK, Ahmed , ARAB, Lakhdar , SAXENA, Geeta , EAVES, Connie, J. , CASHMAN, Johanne , CLARK-LEWIS, Ian , SALARI, Hassan
- 申请人： THE UNIVERSITY OF BRITISH COLUMBIA , Chemokine Therapeutics Corporation
- 申请人地址： Office of Research Services and Industry Liaison,Room 331, I.R.C. Building,2194 Health Sciences Mall Vancouver,British Columbia V6T 1Z3 CA
- 专利权人： THE UNIVERSITY OF BRITISH COLUMBIA,Chemokine Therapeutics Corporation
- 当前专利权人： THE UNIVERSITY OF BRITISH COLUMBIA,Chemokine Therapeutics Corporation
- 当前专利权人地址： Office of Research Services and Industry Liaison,Room 331, I.R.C. Building,2194 Health Sciences Mall Vancouver,British Columbia V6T 1Z3 CA
- 代理机构： Gowshall, Jonathan Vallance
- 优先权： CA2305787 20000509; US205467P 20000519
- 国际公布： WO01085196 20011115
- 主分类号： A61K38/10
- IPC分类号： A61K38/10 ; A61K38/16 ; A61P35/00 ; A61P37/00
摘要：
In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.
公开/授权文献
信息查询
IPC分类:
